TY - JOUR
T1 - Thr92Ala-DIO2 heterozygosity is associated with skeletal muscle mass and myosteatosis in patients with COVID-19
AU - De Lima Beltrão, Fabyan Esberard
AU - De Almeida Beltrão, Daniele Carvalhal
AU - Carvalhal, Giulia
AU - De Lima Beltrão, Fabyanna Lethicia
AU - De Brito Oliveira, Jocyel
AU - Dos Santos Silva, Hatilla
AU - Teixeira, Helena Mariana Pitangueira
AU - Rodrigues, Juliana Lopes
AU - De Figueiredo, Camila Alexandrina Viana
AU - Dos Santos Costa, Ryan
AU - Hecht, Fabio
AU - Vieira, Giciane Carvalho
AU - Da Conceição Rodrigues Gonçalves, Maria
AU - Bianco, Antonio C.
AU - Ramos, Helton Estrela
N1 - Publisher Copyright:
© 2024 the author(s).
PY - 2024/8
Y1 - 2024/8
N2 - Introduction: The type 2 deiodinase and its Thr92Ala-DIO2 polymorphism have been linked to clinical outcomes in acute lung injury and coronavirus disease 2019 (COVID-19). Objective: The objective was to identify a potential association between Thr92Ala-DIO2 polymorphism and body composition (appendicular muscle mass, myosteatosis, and fat distribution) and to determine whether they reflect the severity or mortality associated with the disease. Methods: In this prospective cohort study (June-August 2020), 181 patients hospitalized with moderate-to-severe COVID-19 underwent a non-contrast-enhanced computed tomography (CT) of the thorax to assess body composition, laboratory tests, and genotyping for the Thr92Ala-DIO2 polymorphism. Results: In total, 181 consecutive patients were stratified into three subgroups according to the genotype: Thr/Thr (n = 64), Thr/Ala (n = 96), and Ala/Ala (n = 21). The prevalence of low muscle area (MA) (< 92 cm2) was 52.5%. Low MA was less frequent in Ala/Thr patients (44.8%) than in Thr/Thr (60.9%) or Ala/Ala patients (61.9%) (P = 0.027). Multivariate logistic regression analysis confirmed that the Thr/Ala allele was associated with a reduced risk of low MA (41% to 69%) and myosteatosis (62% to 72%) compared with Thr/Thr + Ala/Ala (overdominant model). Kaplan-Meier curves showed that patients with low muscle mass and homozygosity had lower survival rates than the other groups. Notably, the heterozygotes with MA =92 cm2 exhibited the best survival rate. Conclusion: Thr92Ala-DIO2 heterozygosity is associated with increased skeletal MA and less myosteatosis in patients with COVID-19. The protective effect of Thr92Ala-DIO2 heterozygosity on COVID-19 mortality is restricted to patients with reduced MA.
AB - Introduction: The type 2 deiodinase and its Thr92Ala-DIO2 polymorphism have been linked to clinical outcomes in acute lung injury and coronavirus disease 2019 (COVID-19). Objective: The objective was to identify a potential association between Thr92Ala-DIO2 polymorphism and body composition (appendicular muscle mass, myosteatosis, and fat distribution) and to determine whether they reflect the severity or mortality associated with the disease. Methods: In this prospective cohort study (June-August 2020), 181 patients hospitalized with moderate-to-severe COVID-19 underwent a non-contrast-enhanced computed tomography (CT) of the thorax to assess body composition, laboratory tests, and genotyping for the Thr92Ala-DIO2 polymorphism. Results: In total, 181 consecutive patients were stratified into three subgroups according to the genotype: Thr/Thr (n = 64), Thr/Ala (n = 96), and Ala/Ala (n = 21). The prevalence of low muscle area (MA) (< 92 cm2) was 52.5%. Low MA was less frequent in Ala/Thr patients (44.8%) than in Thr/Thr (60.9%) or Ala/Ala patients (61.9%) (P = 0.027). Multivariate logistic regression analysis confirmed that the Thr/Ala allele was associated with a reduced risk of low MA (41% to 69%) and myosteatosis (62% to 72%) compared with Thr/Thr + Ala/Ala (overdominant model). Kaplan-Meier curves showed that patients with low muscle mass and homozygosity had lower survival rates than the other groups. Notably, the heterozygotes with MA =92 cm2 exhibited the best survival rate. Conclusion: Thr92Ala-DIO2 heterozygosity is associated with increased skeletal MA and less myosteatosis in patients with COVID-19. The protective effect of Thr92Ala-DIO2 heterozygosity on COVID-19 mortality is restricted to patients with reduced MA.
KW - COVID-19
KW - muscle
KW - myosteatosis
KW - Thr92Ala-DIO2
UR - http://www.scopus.com/inward/record.url?scp=85201749820&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85201749820&partnerID=8YFLogxK
U2 - 10.1530/ETJ-24-0068
DO - 10.1530/ETJ-24-0068
M3 - Article
C2 - 38869458
AN - SCOPUS:85201749820
SN - 2235-0640
VL - 13
JO - European Thyroid Journal
JF - European Thyroid Journal
IS - 4
ER -